Metastasis prevention as a formal indication with its own trials and regulatory pathway
Metastasis causes most cancer deaths, yet no drug is developed to stop cells spreading. Create a formal approval route for drugs that prevent metastasis, tested in people at high risk of it.
Drug development targets established tumours; anti-metastatic mechanisms (blocking dissemination, colonisation or pre-metastatic niche formation) fail in trials designed to shrink measurable disease. The proposal is a recognised metastasis-prevention indication: trials in high-risk localised disease or MRD-positive patients with distant-recurrence-free survival as the endpoint, acceptance of mechanistically anti-metastatic agents without expectation of response in bulk disease, and biomarkers of dissemination (circulating tumour cells, ctDNA) as enrichment tools, developed with regulators.
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
Pages like this
not linked directly; found by shared links- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
- IdeaCheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
Shares Metastasis is understood least and studied last, MRD / molecular residual disease testing, Colorectal cancer.
- IdeaBlunt the inflammation that wakes sleeping cancer cells
Shares Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaA ring-fenced metastasis programme with metastasis-specific endpoints
Shares Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
- IdeaBreak the neutrophil DNA nets that catch tumour cells after surgery
Shares Metastasis is understood least and studied last, MRD / molecular residual disease testing, Colorectal cancer.
- IdeaPerioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery
Shares Metastasis is understood least and studied last, Colorectal cancer.
- IdeaAdd a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial
Shares Neoadjuvant / adjuvant / perioperative, Trial design, endpoints and cost.
- IdeaKeep dormant cells asleep instead of trying to kill them
Shares Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.